Evidence map›Paper›PMID 27590141›Full record

ArticleMolecular neurobiology2017

Fasudil Enhances Therapeutic Efficacy of Neural Stem Cells in the Mouse Model of MPTP-Induced Parkinson's Disease.

Yan-Hua Li, Jing-Wen Yu, Jian-Yin Xi, Wen-Bo Yu, Jian-Chun Liu, Qing Wang, Li-Juan Song, Ling Feng, Ya-Ping Yan, Guang-Xian Zhang and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular neurobiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Research progress on intranasal treatment for Parkinson's disease.Neuroprotection (Chichester, England) · 2024
    Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 2 countries.

Yan-Hua LiDepartment of Neurology, Institute of Brain Science, Medical School, Shanxi Datong University, Datong, China.
Jing-Wen YuDepartment of Neurology, Institute of Brain Science, Medical School, Shanxi Datong University, Datong, China.
Jian-Yin XiInstitute of Neurology, Huashan Hospital, Institutes of Brain Science and State Key Laboratory of Medical Neurobiology, Fudan University, Shanghai, China.
Wen-Bo YuInstitute of Neurology, Huashan Hospital, Institutes of Brain Science and State Key Laboratory of Medical Neurobiology, Fudan University, Shanghai, China.
Jian-Chun Liu"2011" Collaborative Innovation Center/Research Center of Neurobiology, Shanxi University of Traditional Chinese Medicine, Taiyuan, China.
Qing Wang"2011" Collaborative Innovation Center/Research Center of Neurobiology, Shanxi University of Traditional Chinese Medicine, Taiyuan, China.
Li-Juan Song"2011" Collaborative Innovation Center/Research Center of Neurobiology, Shanxi University of Traditional Chinese Medicine, Taiyuan, China.
Ling FengDepartment of Neurology, Institute of Brain Science, Medical School, Shanxi Datong University, Datong, China.
Ya-Ping YanNeurological Institute, Tianjin Medical University General Hospital, Tianjin, China.
Guang-Xian ZhangDepartment of Neurology, Thomas Jefferson University, Philadelphia, 19107, PA, USA.
Bao-Guo XiaoInstitute of Neurology, Huashan Hospital, Institutes of Brain Science and State Key Laboratory of Medical Neurobiology, Fudan University, Shanghai, China. bgxiao@shmu.edu.cn.
Cun-Gen MaDepartment of Neurology, Institute of Brain Science, Medical School, Shanxi Datong University, Datong, China. macungen2001@163.com.
Shanxi Datong University · CNShanxi University · CNFudan University · CNHuashan Hospital · CNShanxi University of Traditional Chinese Medicine · CNState Key Laboratory of Medical NeurobiologyThomas Jefferson University · USTianjin Medical University General Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bone marrow-derived neural stem cells (NSCs) are ideal cells for cellular therapy because of their therapeutic potential for repairing and regenerating damaged neurons. However, the optimization of implanted cells and the improvement of microenvironment in the central nervous system (CNS) are still two critical elements for enhancing therapeutic effect. In the current study, we observed the combined therapeutic effect of NSCs with fasudil in an 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson's disease (PD) mouse model and explored the possible cellular and molecular mechanisms. The results clearly show that combined treatment of NSCs with fasudil further improves motor capacity of PD mice, thus exerting double effect in treating MPTP-PD. The combined intervention more effectively protected dopaminergic (DA) neurons from loss in the substantia nigra pars compacta (SNpc), which may be associated with the increased number and survival of transplanted NSCs in the brain. Compared with the treatment of fasudil or NSCs alone, the combined intervention more effectively inhibited the activation and aggregation of microglia and astrocytes, displayed stronger anti-inflammatory and antioxidant effects, induced more neurotrophic factor NT-3, and affected the dynamic homeostasis of NMDA and AMPA receptors in MPTP-PD mice. Our study demonstrates that intranasal administration of NSCs, followed by fasudil administration, is a promising cell-based therapy for neuronal lesions.

Indexed as

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineAnimalsCalcium Channel BlockersDisease Models, AnimalDopaminergic NeuronsMaleMice, Inbred C57BLMicrogliaNeural Stem CellsNeuroprotective AgentsParkinson DiseaseParkinson Disease, SecondarySubstantia Nigra1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineCalcium Channel BlockersfasudilNeuroprotective Agents1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)Bone marrow-neural stem cellsParkinson’s disease (PD)Rho kinase inhibitor fasudil

Identifiers

PMID27590141
OpenAlexW2511076211

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.